323 RESULTS
Sort By:
Quick-and-Early IVIG Therapy: Hints of Promise? Anti-Amyloid Results Show Modest Benefits, Mild Side Effects Wrapping Up Enrollment, ADNI 2, PPMI Focus on Earlier Disease Drug Data Dash at AAN Annual Conference The ANN conference in San Diego covered such
There were so many new data on neurodegenerative disease trials at the recent AAN meeting that organizers crammed some of them into a session of three-minute talks...
Disrupted sleep-wake cycles often accompany neurodegeneration, but scientists are unsure why...
Scientists quipped about Florence as a fitting setting for what they perceive to be a resurgence of the amyloid hypothesis after a beleaguered period of setbacks...
The Alzheimer’s Disease Neuroimaging Initiative steering committee gathered to exchange the latest developments in ADNI 2...
Scientists continue to squeeze every last bit of information out of Phase 3 trials for anti-amyloid antibodies solanezumab and bapineuzumab...
A new AD vaccine co-opts memory T helper cells to cajole B cells into producing anti-Aβ antibodies...
Scientists have turned their attention toward testing therapies in early-stage patients who have underlying brain pathology but little to no functional impairment...
If another small, hopeful trial is to be believed, pooled antibody treatment has the potential to stave off dementia...
Neurofibrillary tangles of tau protein litter Alzheimer’s disease brains, but are they actually bad for neurons?...
DNA damage accrues in Alzheimer's disease and in the aging brain, but would anyone have predicted that neural activity is to blame?...
After more than a decade of seemingly pushing against a wall, BACE inhibitors for Alzheimer’s disease are finally surging forward...
Adding insult to injury, many patients with a movement disorder get dementia, too...
Microglia Activation—Venusberg Meeting Questions M1, M2 Designations Inflammatory Crosstalk Between Periphery and Brain Blessing or Curse? Peripheral Cytokines in the Brain Glial Imaging—Amid Slow Progress, EU Project Takes Up Challenge Venusberg Meeting
Some dismiss it as a therapeutic dead end, but for others, the M1 muscarinic receptor is a target for ongoing drug development research in Alzheimer’s disease...
